144 related articles for article (PubMed ID: 8049631)
1. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
Gilliland F; Becker TM; Smith A; Key CR; Samet JM
Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer in American Indians, New Mexico, 1969 to 1994.
Gilliland FD; Key CR
J Urol; 1998 Mar; 159(3):893-7; discussion 897-8. PubMed ID: 9474177
[TBL] [Abstract][Full Text] [Related]
3. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Merrill RM; Stephenson RA
J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
[TBL] [Abstract][Full Text] [Related]
4. Cancer incidence and mortality in France over the period 1978-2000.
Remontet L; Estève J; Bouvier AM; Grosclaude P; Launoy G; Menegoz F; Exbrayat C; Tretare B; Carli PM; Guizard AV; Troussard X; Bercelli P; Colonna M; Halna JM; Hedelin G; Macé-Lesec'h J; Peng J; Buemi A; Velten M; Jougla E; Arveux P; Le Bodic L; Michel E; Sauvage M; Schvartz C; Faivre J
Rev Epidemiol Sante Publique; 2003 Feb; 51(1 Pt 1):3-30. PubMed ID: 12684578
[TBL] [Abstract][Full Text] [Related]
5. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
6. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer incidence and survival in relation to education (United States).
Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
[TBL] [Abstract][Full Text] [Related]
8. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
10. [Chronological changes of incidence rates, clinical stages and pathological differentiation of prostate cancer in Gunma Prefecture, Japan].
Nakata S; Ohtake N; Kubota Y; Ito K; Suzuki K; Yamanaka H;
Hinyokika Kiyo; 2004 Mar; 50(3):165-70. PubMed ID: 15148767
[TBL] [Abstract][Full Text] [Related]
11. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
12. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Postma R; Roobol M; Schröder FH; van der Kwast TH
Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics of screening-detected prostate cancer on health checkup].
Uchida K; Akaza H
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1527-32. PubMed ID: 9725044
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
16. Quebec prostate cancer mortality dropped in 1996.
Meyer F; Moore L; Bairati I; Fradet Y
Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
[TBL] [Abstract][Full Text] [Related]
17. [Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994].
Visser O; Horenblas S
Ned Tijdschr Geneeskd; 1996 Dec; 140(52):2627-31. PubMed ID: 9026742
[TBL] [Abstract][Full Text] [Related]
18. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
19. [Epidemiology of prostate cancer in the Limousin area].
Druet-Cabanac M; Colombeau P; Preux PM; Paulhac P; Vergnenegre A; Dumas JP
Prog Urol; 2002 Apr; 12(2):226-31. PubMed ID: 12108336
[TBL] [Abstract][Full Text] [Related]
20. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
